FOOTPRINT-CAFÉS
21.4.2016 08:01:21 CEST | Business Wire | Press release
Footprint Cafés, a new chain of sustainable enterprise cafés that will re-invest 100% of net profits into local communities has launched today. The brainchild of Georgina Hemmingway, a graduate of the Judge Business School at the University of Cambridge, Footprint Cafés has also attracted the personal endorsement and financial support of Horizon Discovery Group plc CEO, angel investor and enterprise champion, Dr. Darrin M. Disley who was honoured in the Queen’s Birthday Honours today with a Queen’s Award for Enterprise Promotion.
Footprint Cafés aims to establish itself in every corner of the world, becoming the brand for ethically-motivated tourists, giving them an authentic local experience combined with world class standards. Over the past two year Georgina has already proved the business model works with the success of New Leaf Book café in Siem Reap, Cambodia and is now expanding the concept to the cultural city of Battambang, Cambodia. Darrin Disley, who has become a trustee of the charity, has pledged an initial $150,000 cornerstone donation to a fundraising campaign that aims to raise $1 million by 2017.
Dr. Darrin M. Disley, winner of the Queen’s Award for Enterprise Promotion, commented, “I am delighted to be supporting such a uniquely pure and socially impactful project. Georgina’s idea for Footprint Cafés originated at the Judge Business School and it is fantastic to have been part of her journey and see this come to fruition today.
“Ethical entrepreneurship is at the heart of everything I do and is also a quality which is essential for the development of any successful and sustainable growth business. I am grateful not only to be receiving recognition for the work that I have done, but also to be able support Footprint Cafés mission of addressing global illiteracy, gender inequality and local community development, one fantastic Enterprise Café at a time.”
Footprint Cafés has also launched today a second hand book donation drive. Footprint Cafés will send your donated books to Cambodia, donating any children’s books to rural schools and selling all fiction books in their cafes as holiday reads for tourists. All money raised from book sales in the cafes will be given to the local community as grants for educational projects.
Georgina Hemmingway, Founder of Footprint Cafés, added: “Tourism is one of the fastest growing sectors in the world, and it also represents a significant opportunity to connect and empower local communities. At the moment that opportunity is often wasted with profits being drained off-shore to wealthy owners. Footprint Cafes will connect the global to the local by harnessing the spending power of tourism as a force for local change and empowerment one amazing café at a time.”
-Ends-
About the book drive
Footprint Cafes needs previously loved fiction and children’s books. Individuals are encouraged to write messages inside the books to the unknown Footprint customer. Individuals who would like to donate to the drive are asked to write to Footprint cafes directly to organise collection.
Contact info@footprintcafes.org for details on how to donate your books.
About Footprint Cafés – www.footprintcafes.org
Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.
Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Siem Reap, Cambodia which now employs 17 staff and has generated and donated its profits to eight local organisations tackling illiteracy, gender inequality and community development
The expansion of the model into the cultural city of Battambang, Cambodia supported by the first phase of a $1 million fund-raising drive has already begun with further plans to expand through Indochina and beyond,
About Dr. Darrin M. Disley’s Queens Award
Dr. Darrin M. Disley is the co-founder and Chief Executive Officer of Horizon Discovery Group plc, a successful UK listed life science company based in Cambridge. Dr Disley has made a major contribution to raising the profile of life sciences both in Cambridge and beyond.
As part of his endeavours, he has concentrated on a voluntary programme to raise the profile of entrepreneurship and its connection with life sciences. He has given many hours of time to aid young entrepreneurs through mentoring and speaking engagements. In the past four years, over 100 young entrepreneurs have benefited from his advice, time and financial support and almost a dozen businesses have been launched, raising over ten million pounds in capital. He remains an advisor to many of them.
Darrin also provides assistance to several social enterprises, students from underprivileged backgrounds and advises and assists two universities along with Cambridge University Entrepreneurs.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006628/en/
Contact:
For Media Enquiries
Consilium Strategic Communications
Amber
Fennell, Jessica Hodgson, Matthew Neal
Fennell@consilium-comms.com
Tel:
+44 (0) 203 709 5700
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom